Literature DB >> 21190977

Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells.

Bee K Tan1, Raghu Adya, Jing Chen, Hendrik Lehnert, Louis J Sant Cassia, Harpal S Randeva.   

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women associated with an increased risk of endometrial hyperplasia. We sought to study the effects of metformin treatment (widely used in the management of PCOS women) on human endometrial adenocarcinoma cells.
OBJECTIVES: To study the effects of metformin treatment on in vitro invasion and metastasis in human endometrial adenocarcinoma cells. Also, given the link between inflammation with endometrial cancer invasion and metastasis, we explored the roles of nuclear factor-κB (NF-κB), matrix metalloproteinases (MMPs) as well as v-akt murine thymoma viral oncogene homolog 1 (Akt) and extracellular signal-regulated kinases (Erk(1/2)) signaling pathways.
DESIGN: Sera were obtained from PCOS and control subjects. In vitro invasion were assessed in human endometrial cells (ECC-1 cells) by wound-healing motility and migration assays. NF-κB was studied by stably transfecting ECC-1 cells with a cis-reporter plasmid containing luciferase reporter gene linked to five repeats of NF-κB binding sites. The gelatinolytic activities of secreted MMP-2/9 in conditioned media were measured by gelatin zymography. Akt and Erk(1/2) phosphorylation were assessed by Western blotting.
RESULTS: In vitro invasion in ECC-1 cells was significantly attenuated by sera from PCOS women after 6 months of metformin treatment (850 mg twice daily) compared to matched controls (P < 0.01). These effects appear to be associated with NF-κB, MMP-2/9, as well as Akt and Erk(1/2) pathways that are known to be important regulators of inflammation, tumor invasion and metastasis.
CONCLUSIONS: Metformin, potentially, may serve as adjuvant treatment in the management of patients with endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21190977     DOI: 10.1210/jc.2010-1803

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells.

Authors:  Joshua Kilgore; Amanda L Jackson; Leslie H Clark; Hui Guo; Lu Zhang; Hannah M Jones; Timothy P Gilliam; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 2.  Metformin effects revisited.

Authors:  P Andújar-Plata; X Pi-Sunyer; B Laferrère
Journal:  Diabetes Res Clin Pract       Date:  2011-10-14       Impact factor: 5.602

3.  Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population.

Authors:  Roger C Zhu; Kirk Rattanakorn; Steven Pham; Divya Mallam; Thomas McIntyre; Moro O Salifu; Irini Youssef; Samy I McFarlane; Shivakumar Vignesh
Journal:  Colorectal Cancer       Date:  2017-06-21

Review 4.  Old drug, new trick: repurposing metformin for gynecologic cancers?

Authors:  Terri Febbraro; Ernst Lengyel; Iris L Romero
Journal:  Gynecol Oncol       Date:  2014-10-23       Impact factor: 5.482

5.  Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors.

Authors:  Vijayalekshmi Nair; Satya Pathi; Indira Jutooru; Sandeep Sreevalsan; Riyaz Basha; Maen Abdelrahim; Ismael Samudio; Stephen Safe
Journal:  Carcinogenesis       Date:  2013-06-26       Impact factor: 4.944

6.  Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.

Authors:  Vijayalekshmi Nair; Sandeep Sreevalsan; Riyaz Basha; Maen Abdelrahim; Ala Abudayyeh; Aline Rodrigues Hoffman; Stephen Safe
Journal:  J Biol Chem       Date:  2014-08-20       Impact factor: 5.157

7.  Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma.

Authors:  Guoying Miao; Baoguo Liu; Xiaohui Guo; Xike Zhang; Gui-Jing Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

8.  Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences.

Authors:  Yunzi Wang; Jingping Xiao; Yuanyu Zhao; Shijuan Du; Jiang Du
Journal:  Int J Colorectal Dis       Date:  2020-02-25       Impact factor: 2.571

Review 9.  The effect of environmental chemicals on the tumor microenvironment.

Authors:  Stephanie C Casey; Monica Vaccari; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Mary Helen Barcellos-Hoff; Dustin G Brown; Marion Chapellier; Joseph Christopher; Colleen S Curran; Stefano Forte; Roslida A Hamid; Petr Heneberg; Daniel C Koch; P K Krishnakumar; Ezio Laconi; Veronique Maguer-Satta; Fabio Marongiu; Lorenzo Memeo; Chiara Mondello; Jayadev Raju; Jesse Roman; Rabindra Roy; Elizabeth P Ryan; Sandra Ryeom; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Laura Soucek; Louis Vermeulen; Jonathan R Whitfield; Jordan Woodrick; Annamaria Colacci; William H Bisson; Dean W Felsher
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

10.  Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.

Authors:  Mingzhu Bai; Linlin Yang; Hong Liao; Xiaoyan Liang; Bingying Xie; Ji Xiong; Xiang Tao; Xiong Chen; Yali Cheng; Xiaojun Chen; Youji Feng; Zhenbo Zhang; Wenxin Zheng
Journal:  Oncogene       Date:  2018-06-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.